-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Leriglitazone Hydrochloride in Friedreich Ataxia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Leriglitazone Hydrochloride in Friedreich Ataxia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Leriglitazone Hydrochloride in Friedreich Ataxia Drug Details: Leriglitazone hydrochloride is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Leriglitazone Hydrochloride in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD))
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Leriglitazone Hydrochloride in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Drug Details: Leriglitazone hydrochloride is under development for...
-
Product Insights
Friedreich Ataxia – Drugs In Development, 2023
Global Markets Direct’s, ‘Friedreich Ataxia - Drugs In Development, 2023’, provides an overview of the Friedreich Ataxia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Friedreich Ataxia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BLU-451 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BLU-451 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BLU-451 in Non-Small Cell Lung Cancer Drug Details:BLU-451 (LNG-451) under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atamparib in Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atamparib in Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Atamparib in Lung Cancer Drug Details:Atamparib (RBN-2397) is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – leriglitazone hydrochloride
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry leriglitazone hydrochloride Drug Details Leriglitazone hydrochloride is under development for the treatment of X-linked...
-
Product Insights
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Adrenoleukodystrophy disease is caused by a defect in the gene that tells the body to create lipoproteins. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. The Adrenoleukodystrophy pipeline market research report provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological...